Im­pel con­sid­ers strate­gic al­ter­na­tives, takes out $2.5M loan to con­tin­ue op­er­at­ing

Im­pel Phar­ma­ceu­ti­cals is now con­sid­er­ing strate­gic al­ter­na­tives for its fu­ture, in­clud­ing sell­ing the com­pa­ny as a whole or merg­ing with an­oth­er com­pa­ny, months af­ter ad­mit­ting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER